3billion signs MoU with Kolon Industries to jointly develop gene therapy for rare diseases
On September 1, 3billion signed a Memorandum of Understanding (MoU) with Kolon Industries Future Technology Institute to expand their partnership in developing new gene therapy drugs.…
3billion Announced the Winners of the Second End the Diagnostic Odyssey Grant
3billion recently once again opened up applications for the End the Diagnostic Odyssey Grant. We are once again excited to announce the physicians and researchers that…
3billion meet European doctors and researchers of rare disease diagnostics by participating in ESHG 2022
3billion is participating in the 'European Society of Human Genetics Annual Conference(ESHG 2022)' to in Vienna, Austria from June 11 to 14 (local time)…
3billion Wins in CAGI6, a Global Artificial Intelligence Genome Interpretation Contest
In the 6th CAGI(Critical Assessment of Genome Interpretation) Challenges, a global artificial intelligence genomic interpretation contest, 3billion took first place by predicting the rare diseases…
3billion’s article on EVIDENCE was selected as Top Cited Article in Wiley Online Library
A research paper on 3billion's automated variant prioritization system, EVIDENCE, published in Wiley's Clinical Genetics Journal in December 2020, was selected as the ‘Top Cited Article’…
3billion was selected as a business operator for the national project
3billion plans to form a consortium with Seoul National University Hospital and Kakao Healthcare to develop an AI integrated software solution for multifaceted analysis of rare…
3billion Company Video: From 3 billion bases to 1 answer
3billion released a company video explaining why rare disease is so difficult to diagnose and how 3billion is solving them. Check out the video and learn…
3billion aims to lead genetic diagnosis in global market
Let’s take a look at the interview article with ‘Korea Biomedical Review’ of 3billion’s CEO Changwon Keum. There are many difficulties in diagnosing rare…
3billion will be at ACMG 2022
Diagnostic performance of automated, streamlined, daily updated exome analysis in patients with neurodevelopmental delay3billion announced that Chief Medical Officer Dr. Gohun Seo will be introducing a…
3billion Announced the Winners of the End the Diagnostic Odyssey Grant
3billion recently announced the first recipients of the End The Diagnostic Odyssey Grant. The grant was offering a total of up to $1,000,000 of…
3billion receives accreditation from the College of American Pathologists
3billion has received CAP accreditation on November 15th. CAP accreditation is an evaluation system by the College of American Pathologists, an organization of clinical pathologists in…
3billion selected as a finalist of the Novartis Korea’s Health X-Challenge Seoul
On December 8th, 3billion was selected as a finalist of the Novartis Korea’s Health X-Challenge Seoul for the ‘Genetic retinal disease’ category. 3billion was highly…